Posts by Mourabit Halima

The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.

At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the Infectious Tumors Subcommittee session, Dr. Qingbo Wang from The Second Hospital of Nanjing presented a report titled "Comprehensive Treatment Strategies for Tuberculosis-Associated Lung Cancer." The presentation explored the epidemiology, diagnostic challenges, and treatment strategies for patients with coexisting tuberculosis (TB) and lung cancer.

With advancements in local treatment techniques and the emergence of new therapeutic agents, combined local and systemic therapies have demonstrated synergistic effects greater than the sum of their parts in liver cancer management. For patients with intermediate and advanced liver cancer, this approach has improved conversion therapy success rates and even achieved curative outcomes. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), during the "Interventional Oncology" session, Dr. Ming Zhao from the Sun Yat-sen University Cancer Center shared his insights on the combined treatment approach. Oncology Frontier interviewed Professor Zhao to discuss the theoretical foundations, current developments, and future directions of combined local and systemic therapies.

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) opened grandly in the ancient city of Xi’an on November 16, focusing on the theme "Winning Against Cancer Through Integration." This conference brought together global medical elites to strategize for global health solutions. During the event, conference chair and President of the China Anti-Cancer Association (CACA), Academician Daiming Fan, shared insights in an interview with Oncology Frontier. He delved into the pivotal role of integrative medicine in advancing global medical progress and its profound impact on the future of healthcare.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy (CTI) Conference was held in Hangzhou, China, bringing together leading global experts, scholars, and industry leaders in the field of cell and immunotherapy. This conference served not only as a platform for academic exchange but also as a vital window to showcase cutting-edge research and drive advancements in the field. Dr. Peihua Lu, a pioneer in CAR-T clinical trials and a leader at Beijing Lu Daopei Hospital, shared groundbreaking progress on CAR-T therapies for T-cell malignancies at CTI 2024, following earlier presentations on CD7 CAR-T therapy for T-ALL/LBL at The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024)  meeting. In an exclusive interview with Hematology Frontier, Professor Lu discussed strategies for applying CAR-T therapy across different types and stages of T-cell malignancies, China’s role in global CAR-T research, and the importance of international collaboration.